ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn


Product Timeline
Click to Enlarge

What Sets Us Apart

RK-01 is mechanistically and clinically different from currently marketed drugs.  It is an innovative and novel 'Beta-cell centric' combination product. RK-01 fills clinically the most important gap that exists in the modalities used for the drugs on the market. Currently, there are no pancreatic 'beta-cell centric' products on the market. RK-01 will be custom formulated to provide sustined glycemic control by maintaining or restoring beta-cell function and decreasing insulin resistance. FDC (Fixed Dose Combination) tablets or capsules will also reduce the pill burden and achieve better efficacy, safety, and patient compliance.

ARKAY is collaborating with Dr. Robert Busch, MD at Albany Medical College to conduct an investigator-initiated human PoC study to evaluate the superiority of RK-01 (Valsartan plus Celecoxib dual add-on to Metformin-HCL XR) over Metformin monotherapy in Type 2 diabetes patients with inadequate glycemic control. Dr. Busch is a diabetes expert; he has served as a Principal Investigator in over 40 clinical studies.

If you are interested in investing in our biopharmaceutical company, click here. For any general questions on our operations, reach us at (609) 362-6818.


About Us

Type 2 diabetes is a progressive inflammatory disease. It is characterized by insulin resistance and pancreatic beta cell failure. Elevated fasting glucose levels, impaired glucose tolerance, and impairment of the first and the second phase of glucose-dependent insulin secretion (GDIS) are hallmarks of the disease. Inflammation-triggered deterioration of pancreatic beta cell function compromises their inherent capacity to compensate for insulin resistance. Pro-inflammatory signals originating from the activation of immune dysregulation, Renin-Angiotensin System (RAS) and Cyclooxygenase-2 (COX-2) contribute to the reduction in the beta-cell mass and consequential state of insulin dependence.  There is a direct cause and effect relationship between the elevation of Prostaglandin E2 and inhibition of glucose-stimulated insulin secretion (GSIS) as well as destruction of beta cells. Functional response of beta cells and insulin sensitivity of insulin-responsive tissues such as liver, fat and skeletal muscle are tightly regulated by a feedback loop. This feedback loop determines the normal regulation of glucose metabolism by adjusting the glucagon-insulin molar ratio. There is a direct correlation between the magnitude of beta cells response and sensitivity of insulin-responsive tissues to insulin. As tissues develop insulin resistance, beta cells compensate with an increased output of insulin. Blood glucose levels rise in the presence of insulin resistance when beta cells are incapable of releasing sufficient insulin due to progressive deterioration of beta cell function. If pro-inflammatory signals are not blocked with the right combination of drugs, there will be progressive reduction in pancreatic beta cell mass due to inflammation-triggered apoptosis which leads to an irreversible state of pancreatic beta cell failure, a stage at which Type 2 diabetes becomes indistinguishable from Type 1 diabetes. The only treatment option available to patients at that stage is insulin therapy.

Major Pathophysiologic Defects in Type 2 Diabetes
Click to Enlarge
Beta Cell Destruction
Click to Enlarge

In spite of intense mono- and combination therapies with the existing modalities, patients experience deterioration of metabolic control of glucose homeostasis which is indicative of progressive deterioration of beta cell function. ARKAY is committed to filling clinically the most important gap that exists in the modalities used for the treatment options by targeting multiple distinct and overlapping mechanisms along the immune dysregulation-inflammation-insulin resistance axis that contribute to beta cell dysfunction. The complex etiology of Type 2 diabetes involves impairment of function of a variety of cell types that contribute to deterioration of beta cell function which triggers insulin resistance. ARKAY is advancing an innovative and novel anti-inflammatory 'Beta-cell-centric' platform that treats beta-cell dysfunction and maintains its inherent capacity to compensate for insulin resistance.

Recently, Dr. Stan Schwartz, MD one of ARKAY's medical advisors described the 'Egregious Eleven' pathways and defects that contribute to hyperglycemia in his 'Beta-cell-centric' construct with beta-cell damage as the FINAL COMMON DENOMINATOR (Diabetes Care 2016; 39:179-186). To provide long-term sustainable glycemic control, the ideal therapeutic option has to favorably modulate maximum number of the 'Egregious Eleven' pathways with a minimum number of orally-active active drugs that are safe for chronic use in the early stages of progressive deterioration of beta-cell function soon after a patient is diagnosed for Prediabetes or Type 2 diabetes when pancreas still contains a restorable critical mass of beta cells.

RK-01 blocks many of these pathways which we anticipate would contribute to long-term sustainable glycemic control, prevent or delay  the initiation of insulin therapy as well as prevent, delay or reduce the severity of diabetes-related complications. More importantly, It is expected to prevent primary and secondary failure of Metformin, the current standard of care. ARKAY's scientific rationale and the product concept is supported further by the consensus opinion of experts of the ADA, AACE, EASD and JDRF which highlighted the importance of targeting inflammation-mediated beta-cell destruction, progressive deterioration of beta-cell function and emphasized their role in the natural history of the pathophysiology of diabetes (Skyler, J.S. et al. 2017; Diabetes 66: 241-255). We are on track to bring our novel and innovative orally-active 'Beta-cell centric' combination product, RK-01 to the market by 2024.


ParamAushadam®

Derived from Sanskrit, it means "Perfect Medicine" in English.

Precision Medicine: A pharmaceutical finished product methods and formulations technology platform that combines therapeutically efficacious doses of drugs with predetermined modified drug release kinetics to achieve optimal therapeutic synergies by sparing adverse side effects as well as eliminating potential drug-drug interactions.

"Synergistically improved pharmaceutical made from a combination of pharmaceuticals for use in the treatment of diabetes; synergistically improved pharmaceutical made from a combination of pharmaceuticals for the treatment of obesity-triggered diseases, namely, diabetes and breast cancer; synergistically improved pharmaceutical made from a combination of pharmaceuticals for the treatment of conditions that coexist with diabetes, namely, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), arthritis and polycystic ovarian syndrome (PCOS); synergistically improved pharmaceutical made from a combination of pharmaceuticals for the treatment of diabetes-related complications, namely, nephropathy, retinopathy, neuropathy, stroke and skin ulcers"

ParamAushadam